Key clinical point: Use denosumab as second line after bisphosphonate therapy to reduce BMD loss at its discontinuation.
Major finding: BMD losers (those losing at least 3.96%) were less likely to use zoledronate before starting denosumab (0% vs. 12%) and had greater serum CTX levels at denosumab initiation (644 ng/mL vs. 474 ng/mL).
Study details: A longitudinal cohort study of 170 postmenopausal women with osteoporosis at Lausanne (Switzerland) University Hospital who are taking denosumab therapy.
Disclosures: The presenter disclosed serving on speakers bureaus for Eli Lilly, Pfizer, Amgen, and Novartis.
Aubry-Rozier B et al. Ann Rheum Dis. Jun 2019;78(Suppl 2):115. Abstract OP0085. doi: 10.1136/annrheumdis-2019-eular.4175.